← Back to Screener
Celldex Therapeutics, Inc (CLDX)
Price$31.27
Value ScoreF
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-2.00%
Price vs S&P 500 (4W)-0.57%
VGM Score27.14
Market Capitalization$2.45B
All Metrics
Book Value / Share (Quarterly)$6.85
P/TBV (Annual)3.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-13.17%
Cash Flow / Share (Quarterly)$-3.40
Price vs S&P 500 (YTD)6.36%
Gross Margin (TTM)17.65%
Net Profit Margin (TTM)-25011.78%
EPS (TTM)$-4.27
10-Day Avg Trading Volume0.80M
EPS Excl Extra (TTM)$-4.27
Revenue Growth (5Y)-26.94%
EPS (Annual)$-3.90
ROI (Annual)-49.08%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-5465.53%
Cash / Share (Quarterly)$6.78
Revenue Growth QoQ (YoY)-97.84%
ROA (Last FY)-44.38%
Revenue Growth TTM (YoY)-88.54%
EBITD / Share (TTM)$-4.60
ROE (5Y Avg)-30.88%
Operating Margin (TTM)-27187.64%
Cash Flow / Share (Annual)$-3.21
P/B Ratio5.38x
P/B Ratio (Quarterly)4.63x
Net Income / Employee (Annual)$-1,306,900
EV / Revenue (TTM)2792.98x
Net Interest Coverage (TTM)-740.36x
ROA (TTM)-46.59%
EPS Incl Extra (Annual)$-3.90
Current Ratio (Annual)10.49x
Quick Ratio (Quarterly)8.78x
3-Month Avg Trading Volume0.95M
52-Week Price Return53.66%
Revenue / Employee (TTM)$4,400
Tangible BV / Share (Quarterly)$6.45
P/S Ratio (Annual)1588.64x
Asset Turnover (Annual)0.00x
52-Week High$35.79
Operating Margin (5Y Avg)-6007.73%
EPS Excl Extra (Annual)$-3.90
CapEx CAGR (5Y)11.86%
Tangible BV CAGR (5Y)22.86%
26-Week Price Return6.18%
Quick Ratio (Annual)10.21x
13-Week Price Return4.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.92x
Enterprise Value$2.42B
Revenue / Share Growth (5Y)-37.80%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)8.43%
Revenue / Employee (Annual)$7,800
Inventory Turnover (Annual)0.80x
Pretax Margin (Annual)-16748.03%
Cash / Share (Annual)$7.79
3-Month Return Std Dev42.59%
Gross Margin (5Y Avg)44.59%
Net Income / Employee (TTM)$-1,432,600
ROE (Last FY)-49.08%
Net Interest Coverage (Annual)-55.51x
EPS Basic Excl Extra (Annual)$-3.90
P/FCF (TTM)78.82x
Receivables Turnover (TTM)1.34x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.27
Receivables Turnover (Annual)1.14x
ROI (TTM)-50.72%
P/S Ratio (TTM)2834.23x
Pretax Margin (5Y Avg)-5466.52%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$7.51
Price vs S&P 500 (52W)30.80%
Year-to-Date Return15.13%
5-Day Price Return9.49%
EPS Normalized (Annual)$-3.90
ROA (5Y Avg)-28.48%
Net Profit Margin (Annual)-16748.03%
Month-to-Date Return-0.51%
Cash Flow / Share (TTM)$-2.58
EBITD / Share (Annual)$-4.28
Operating Margin (Annual)-18599.81%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-30.88%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.27
P/TBV (Quarterly)4.92x
P/B Ratio (Annual)3.42x
Inventory Turnover (TTM)0.80x
Pretax Margin (TTM)-25011.78%
Book Value / Share (Annual)$7.92
Price vs S&P 500 (13W)-6.71%
Beta0.87x
P/FCF (Annual)144.55x
Revenue / Share (TTM)$0.01
ROE (TTM)-50.72%
52-Week Low$19.52
vGradeF
gGradeF
mGradeB
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.18est. -1.16
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.05
4.14
4.23
4.23
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLDXCelldex Therapeutics, Inc | F | F | B | $31.27 |
| IDXXIdexx Laboratories Inc | D | B | C | $560.88 |
| LNTHLantheus Holdings, Inc | C | B | B | $104.52 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | D | $15.59 |
| NEOGNeogen Corp | C | C | B | $9.10 |
| NTLAIntellia Therapeutics, Inc | D | C | C | $12.11 |
| QDELQuidelOrtho Corporation Common Stock | C | C | D | $14.13 |
| ACHVAchieve Life Sciences, Inc. | F | F | A | $5.52 |
| MYGNMyriad Genetics Inc | C | C | C | $4.33 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | C | $4.20 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | B | $5.61 |
About
Celldex Therapeutics develops monoclonal and bispecific antibodies to treat mast cell-mediated inflammatory, allergic, and autoimmune diseases. The company combines research in mast cell biology with manufacturing and commercialization capabilities to advance its therapeutic pipeline.